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Abstract
Intracellular calcium is a powerful secondary messenger that affects a number of calcium sen-
sors, including calpain, a Ca2+-dependent cysteine protease, and calcineurin, a Ca2+/calmodulin-
dependent protein phosphatase. Maintenance of low basal levels of intracellular calcium allows for
the tightly regulated physiological activation of these proteins, which is crucial to a wide variety of
cellular processes, such as fertilization, proliferation, development, learning, and memory. Dereg-
ulation of calpain and calcineurin has been implicated in the pathogenesis of several disorders,
including hypertension, heart disease, diabetes, cerebral ischemia, and Alzheimer’s disease. Re-
cent studies have demonstrated an interplay between calpain and calcineurin, in which calpain can
directly regulate calcineurin activity through proteolysis in glutamate-stimulated neurons in cul-
ture and in vivo. The calpain-mediated proteolytic cleavage of calcineurin increases phosphatase
activity, which promotes caspase-mediated neuronal cell death. Thus, the activation of the calpain-
calcineurin pathway could contribute to calcium-dependent disorders, especially those associated
with Alzheimer’s disease and myocardial hypertrophy. Here, we focus briefly on recent advances
in revealing the structural and functional properties of these 2 calcium-activated proteins, as well
as on the interplay between the 2, in an effort to understand how calpain-calcineurin signaling may
relate to the pathogenesis of calcium- dependent disorders.
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alpain and calcineurin are 2 important eﬀ ec-
tors of the intracellular actions of calcium. 
Calpain is a Ca2＋-activated neutral cysteine protease 
that catalyzes limited proteolysis of substrate pro-
teins.  Calcineurin is a widely distributed class of 
protein phosphateses and belongs to the protein phos-
phatase 2B family of Ca2＋/calmodulin-dependent ser-
ine/threonine protein phosphatases [1,  2]. 
Activation of these 2 proteins by calcium levels in 
the physiological range has widespread eﬀ ects,  from 
the direct eﬀ ects of proteolysis and dephosphoryla-
tion of target proteins,  to the indirect modulation of 
diverse downstream signaling pathways.  This regu-
lated cleavage by calpain and dephosphorylation by 
calcineurin is critical in a variety of cell processes, 
including cell embryonic development,  proliferation, 
diﬀ erentiation,  migration,  cell cycle progression, 
meiosis,  and mitosis [3ﾝ12].  Deregulation of calpain 
and calcineurin,  caused by a disruption of calcium 
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homeostasis,  is critically involved in the pathogenesis 
of several important calcium-dependent diseases, 
such as hypertension,  heart disease,  diabetes,  and 
Alzheimer’s disease.  Moreover,  under certain patho-
logical conditions,  calpain and calcineurin may inter-
act,  and this interaction may play a role in the patho-
genesis of many calcium-dependent disorders.  Here 
we provide an overview of Ca2＋-dependent activation 
of calpain and calcineurin at the molecular and cellu-
lar levels and discuss the potential interplay between 
the 2 in the pathogenesis of calcium-dependent disor-
ders.
General Properties of the Calpain Family
　　Calpains function as cytoplasmic cysteine protein-
ases,  regulatory enzymes transducing intracellular 
Ca2＋ signals into the controlled proteolysis of their 
substrates.  Because of the presence of numerous 
downstream targets in a variety of signaling path-
ways,  calpains are speculated to play important roles 
in cytoskeletal remodeling,  cell diﬀ erentiation,  apop-
tosis,  necrosis,  embryonic development,  and long-
term potentiation in the central nervous system.  The 
overactivation of calpain is connected to a number of 
diseases,  including muscular dystrophy,  cardiac and 
cerebral ischemia,  traumatic brain injury,  platelet 
aggregation,  restenosis,  neurodegenerative diseases, 
rheumatoid arthritis,  and cataracts,  making calpain 
an attractive drug target [13ﾝ18].
　　Calpains are intracellular nonlysosomal Ca2＋-reg-
ulated cysteine proteases ubiquitously found in ani-
mal tissues [19].  Based on human sequence homol-
ogy,  14 human genes have been identiﬁ ed as members 
of the calpain large catalytic 80 kDa family,  and 2 
human genes for the small regulatory 30 kDa family 
[20,  21] (Table 1).  The large catalytic subunit of 
calpains consists of 2 groups,  typical and atypical, 
containing nine and 6 members,  respectively. 
Calpains 1,  2,  3a,  3b,  8,  9,  11,  12,  and 13 are 
typical calpains characterized by a C-terminal Ca2＋
-binding domain that includes an EF-hand motif.  The 
small optic lobe homology,  including calpains 5,  6,  7, 
8b,  10a,  and 15,  are atypical calpains ; they lack 
EF-hand motifs and contain additional domains diﬀ er-
ent from those of typical calpains.  Among the typical 
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Table 1　　The General information of calpain family
Common Name Gene Used Name Distribution Species
Amino
Acid
Residues
Typical Calpain
Calpain 1 Capn1 µ-Calpain Ubiquitous Mammalian 714
Calpain 2 Capn2 m-Calpain Ubiquitous Mammalian 700
Calpain 3a Capn3 nCL-1,  p94 Skeletal muscle Mammalian 821
Calpain 3b Capn3 Lp82 Lens Mammalian 821
Calpain 8a Capn8 nCL-2 Stomach Mammalian 703
Calpain 9 Capn9 nCL-4 Digestive tracts Mammalian 690
Calpain 11 Capn11 Testis Mammalian 702
Calpain 12 Capn12 Hair follicle Mammalian 720
Calpain13a
Calpain 13b
Capn13 Ubiquitous Mammalian 423
Atypical Calpain
Calpain 5 Capn5 nCL-3,  htra3 Ubiquitous Mammalian 640
Calpain 6 Capn6 CANPX Placenta,
Embryonic 
muscle
Mammalian 641
Calpain 7 Capn7 palBH Ubiquitous Mammalian 813
Calpain 8b Capn8 nCL-2 Stomach Mammalian 703
Calpain 10 Capn10 Ubiquitous Mammalian 672
Calpain 15 Capn15 SOLH Ubiquitous Mammalian 1,086
Small Calpain
Small Subunit I Capn 4  (SOL) Ubiquitous Mammalian 268
Small Subunit II Capn14 Mammalian 248
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calpains,  ｻ- and m-calpains (also called calpain I and 
calpain II,  respectively) are the most characterized 
heterodimeric members.  They are encoded by genes 
CAPN1 and CAPN2 in mammalians.  Based on amino 
acid sequence comparisons,  the large subunit of 
ｻ-calpain and that of m-calpains are each comprised 
of up to 4 distinct domains (I-IV ; Fig.  1).  The 
N-terminal region contains residues 1ﾝ19 and is a 
single ｸ-helix ; it can interact with domain VI of the 
small subunits and may be important for stability. 
Domain II is known to carry residues Cys105, 
His262,  and the Asn286 triad,  which are responsible 
for calpain catalytic activity.  It is structurally simi-
lar to the catalytic domains of other cysteine prote-
ases,  such as papain,  caspases,  and cathepsins B,  L, 
and S.  This domain is composed of 2 subdomains ﾝ
IIa (residues 20ﾝ210) and IIb (residues 211ﾝ355) ﾝ
and a substrate binding cleft.  Subdomain IIa includes 
the catalytic Cys105,  while subdomain IIb contains 
the His262 and Asn286 residues of the catalytic 
triad [22,  23].  Domain III (residues 356ﾝ514) can 
bind Ca2＋and consists of eight ｹ-strands arranged in 
a ｹ-sandwich conﬁ guration similar to those of C2 
domains,  a stretch of approximately 130 amino acids 
that binds phospholipids in a Ca2＋-dependent manner 
found in phospholipase C,  protein kinase C, and so 
on [24,  25].  Domain IV (residues 531ﾝ700),  at the 
C-terminal end of the large subunit, is a Ca2＋-binding 
domain structurally containing 5 sets of EF-hand 
similar to those found in calmodulin [26ﾝ28].  In 
addition,  there is a long,  exposed linker region span-
ning through amino acid residues 516ﾝ530 between 
domains III and IV.  The small 30 kDa regulatory 
subunit contains 2 domains.  Domain V (residues 1ﾝ
101),  the N-terminal region of the small subunit,  is a 
hydrophobic domain rich in glycine and may function 
as a membrane anchor.  Domain VI (residues 102ﾝ
268),  the C-terminal end of the small subunit,  is a 
Ca2＋-binding region similar to domain IV of the large 
subunit [29ﾝ30].  The large catalytic subunit associ-
ates with the small regulatory subunit through the 
extreme C-terminal ﬁ fth EF-hand motif in IV and VI 
to form a heterodimeric calpain [29,  31ﾝ33].
Ca2＋-dependent Calpain Activation
　　An understanding of the molecular-level details of 
calpain activation is crucial for comprehending the 
functional properties of this protease and its charac-
terization of pathophysiological signiﬁ cance in many 
diseases.  X-ray structural analyses have revealed 
that there are at least 3 diﬀ erent Ca2＋-binding sites 
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Fig. 1　　Schematic representation of domain architecture of the classical calpains.  The catalytic subunit possesses domains I-IV. 
Domain I contains residues 1ﾝ19 and interacts with domain VI of the small subunits.  Domain II contains residues 20ﾝ355 and is divided 
into 2 subdomains,  IIa and IIb,  which carry residues of Cys105,  His262,  and the Asn286 triad responsible for calpain catalytic activity. 
Domain III contains residues 356ﾝ514, which harbors the C2 area that binds phospholipids.  Domain IV contains residues 515ﾝ700 and is 
the C-terminal end of the large subunit.  It consists of 5 consecutive EF-hand motifs.  The regulatory subunit contains domain V,  which is 
a highly ﬂ exible,  glycine-rich region,  and domain VI,  which is a Ca2＋ binding region,  similar to domain IV of the catalytic subunit.　
3
Wu et al.: Calpain-calcineurin signaling in the pathogenesis of calcium-depe
Produced by The Berkeley Electronic Press, 2007
in m-calpain : the two EF-hands (calmodulin-like 
domains IV and VI),  the cysteine catalytic region 
(domain II),  and the acidic loop (C2-like domain III) 
[23,  30,  34].  In the absence of Ca2＋,  the 2 subdo-
mains of the catalytic subunit, IIa and IIb,  are sepa-
rated by a deep crevice,  thus maintaining the active 
site in a state in which the catalytic triad residues 
are under a structural conformation that does not 
allow for substrate hydrolysis (Fig.  2).  In this con-
formation,  subdomain IIa is restrained by a circular 
arrangement of domain I,  the N-terminal anchor pep-
tide,  binding to domain IV.  Subdomain IIb is bound 
by an acidic loop in domain III [35ﾝ37].  When cal-
cium binds to these domains,  a major conformational 
change occurs that ultimately produces a competent 
active site in the cysteine protease region.  Studies 
have suggested that calpains undergo a Ca2＋-depen-
dent two-stage activation [37,  Fig.  2].  At the ﬁ rst 
stage,  the binding of calcium to domain III and two 
EF-hand regions results in an auto-cleavage of 
domain I,  eliminating the N-terminal link between the 
large 80 kDa catalytic subunit and the small 30 kDa 
regulatory subunit.  This calcium binding would allow 
movement within domain II,  in which subdomain IIb 
turns over towards subdomain IIa,  thereby forming 
an active site [34,  38ﾝ47].  At the second stage of 
activation,  the binding of calcium directly to the cys-
teine residue causes a shift in the conformation 
where subdomains IIa and IIb reposition the catalytic 
site cleft to a spatial arrangement favorable for sub-
strate hydrolysis.  This proposed two-stage Ca2＋
-dependent process is a general activation mechanism 
for calpain superfamily members.  The activation 
mechanism for the nonheterodimeric calpains that do 
not contain small subunits and those lacking EF-hand 
or C2-like domains in the large subunit could be 
alterative.  Unlike the cysteine catalytic site (domain 
II) present in all members of the calpain superfamily, 
the ﬂ anking domains ﾝ domains III,  IV,  and VI ﾝ are 
varied in atypical calpains [48].  These nonheterodi-
meric calpains could be directly activated by the 
cooperative binding of Ca2＋ to domain II without the 
ﬁ rst stage of activation.
Inhibition of Calpain Activities
　　Because calpain irreversibly cleaves numerous 
signaling and structural proteins,  with widespread 
impact on cell functioning and viability,  the protease 
activity is highly controlled in vivo by multiple mecha-
nisms,  including phosphorylation and an endogenous 
inhibitor,  calpastatin [49,  50].  Calpastatin is an 
interacting partner of calpain that is capable of inhib-
iting calpain activity.  The binding of calpastatin to 
calpain is a Ca2＋-dependent event and is reversible 
[51,  52].  Studies have suggested that binding of 
calpastatin to calpain occurs before calpain can initi-
ate proteolytic activity,  as the Ca2＋concentration 
required for calpastatin binding to calpain is less 
than the Ca2＋concentration required for the half-
maximal proteolytic activity of μ- and m-calpains [52, 
53].  Although calpastatin is the only known inhibitor 
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Fig. 2　　Calcium-dependent calpain activation.  Fig. 2 was adapted from [21] and represents the activation mechanism of calpain by 
Ca2＋.  A shows activation in the absence of Ca2＋ ; the 2 subdomains of the catalytic subunit,  IIa and IIb,  are separated by a deep crev-
ice.  B shows the binding of Ca2＋ and phospholipids (PL) to calpain,  initiating a series of structural movements that result in IIa and IIb 
close together to form a functional catalytic site.
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with absolute speciﬁ city for both μ- and m-calpains, 
it possesses a large molecular mass,  making it cell-
impermeable,  and thus has limited therapeutic use.
　　Calpastatin has 4 repeating,  marginally homolo-
gous (23ﾝ36ｵ) inhibitory domains (I-IV),  each having 
approximately 140 amino acid residues,  and an 
N-terminal domain L that has no inhibitory activity 
(Fig.  3) [54ﾝ57].  Each individual domain consists of 
3 subdomains,  A,  B,  and C,  with subdomain B play-
ing a central role in calpain inhibition [58ﾝ60].  A 
27-residue peptide (CS),  containing most of subdo-
main B from domain I of human calpastatin,  is a 
potent and speciﬁ c inhibitor of calpain in vitro but has 
little ability to translocate across the cell membrane. 
However,  fusion of this CS peptide to a protein 
transduction domain,  an 11 poly-arginine peptide 
(11R),  allows it to be cell-permeable and eﬀ ectively 
inhibits calpain activity [61,  62ﾝ64].  Studies have 
compared in vitro inhibitory ability between 11R-CS 
and the natural peptide CS on calpain auto-cleavage 
in cultured hippocampal neurons,  and found that the 
IC50 values are 0.48 ｻM for CS and 0.51 μM for 
11R-CS [62].  Application of the 11R-CS to hippo-
campal cultures at a concentration of 50 ｻM substan-
tially protects neurons from 500 ｻM glutamate-
induced excitotoxicity [63].
　　Phosphorylation is another way to control calpain 
acitivity.  Calpain has several phosphorylation sites. 
One of them is phosphorylated by protein kinase A 
(PKA),  which negatively regulates calpain activity. 
It has been reported that domain III of the human 
m-calpain large subunit is directly phosphorylated in 
vitro at Ser369 or Thr370 by PKA [65,  66]. 
Ser369/Thr370 is located in the interface region 
between domains III and IV,  and phosphorylation of 
these sites presumably leads to contact between these 
domains,  which can prevent the formation of the cal-
pain active cleft.  The biological role of PKA-
mediated phosphorylation of m-calpain has been 
determined in living cells.  In NR6WT mouse ﬁ bro-
blasts,  phosphorylation of m-calpain by PKA at Ser 
369 or Thr370 decreases epidermal growth factor 
(EGF)-induced activation of m-calpain and inhibits 
ﬁ broblast migration [65].
　　In addition,  inhibitors derived from natural 
sources or produced synthetically have been devel-
oped and proven to be eﬀ ective against calpain activ-
ity.  For example,  the representative peptidyl epoxy-
succinate inhibitors are trans-epoxysuccinyl-L-
leucylamido-4-guanidino-butane (E64) and its 
derivative,  E64d ; peptidyl aldehyde inhibitors 
include leupeptin,  calpain inhibitor I,  calpain inhibi-
tor II,  calpeptin,  and MDL28170.  These inhibitors 
inactivate calpain reversibly or irreversibly by form-
ing a covalent bond with the active site thiolate or 
interacting with the Ca2＋-binding domain of the cal-
pain large subunit [67] ; they show speciﬁ city for 
calpains over other cysteine proteases and low cell 
membrane permeability [68].
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A B CA B C A B C A B CN-ter.
Domain L Domain I Domain II Domain III Domain IV
C-ter.
149 283 426 563 708
Calpastatin Peptide (CS): DPMSSTYIEELGKREVTIPPKYRELLA
11R: RRRRRRRRRRR
11R-CS: MRRRRRRRRRRRGDPMSSTYIEELGKREVTIPPKYRELLA
Fig. 3　　Schematic diagram showing the domain structure of human calpastatin,  calpastatin peptide (CS),  [11] arginine (11R),  and 
11R-fused CS.  Calpastatin is comprised of an N-terminal domain L and four repeated domains,  each of which contains 140 amino acid 
residues.  A,  B,  and C regions are subdomains having signiﬁ cant sequence homology within each domain.  Subdomain B contains a 
highly conserved sequence that has been implicated in calpain inhibition.  CS is a 27-residue oligopeptide encoded by exon 1B of human 
calpastatin.  11R is an eﬀ ective protein transduction domain including 11 poly-arginine peptides.
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General Properties of Calcineurin
　　Calcineurin is a heterodimer consisting of a cata-
lytic subunit (calcineurin A) with a molecular mass of 
about 57ﾝ59 kDa and a regulatory calcium-binding 
subunit (calcineurin B) with a molecular mass of 
19 kDa [69].  These subunits are tightly associated 
and can be dissociated only by the use of denaturants 
[70].  Calcineurin is ubiquitously distributed in 
eukaryotes and widely distributed in the brain,  with 
high levels in the hippocampus and caudate putamen 
[69,  71ﾝ76].  Immunohistochemistry and in situ 
hybridization have shown the presence of calcineurin 
A in cell bodies,  postsynaptic densities (PSDs),  den-
drites,  axons,  and spines.  Within the cell,  approxi-
mately half of the calcineurin population is in the 
cytosol,  and the other half is associated with the 
plasma membrane [69].  Calcineurin is largely absent 
from glia and interneurons in the hippocampus [77].
　　Calcineurin has intrinsic Ca2＋-binding properties 
[71,  78].  Structural and functional analyses suggest 
that calcineurin B contains four “EF”-hand,  Ca2＋
-binding sites,  a myristoylated-binding domain,  and 
an aﬃ  nity for calcineurin A [79ﾝ81].  Mammalians 
have 3 isoforms of calcineurin A (ｸ,  ｹ,  and ｺ,  also 
called ｸ1,  ｸ2,  and ｸ3) and 2 of calcineurin B,  B1 
and B2 [82ﾝ85].  Expression of calcineurin Aｺ and 
B2 is restricted to the testis,  while calcineurin Aｸ, 
Aｹ,  and B1 are expressed in a wide spatiotemporal 
distribution [86].
　　The active site of calcineurin is located on the A 
subunit (Fig.  4).  The catalytic subunit calcineurin A 
(521 residues) contains a phosphatase domain (resi-
dues 1ﾝ328),  a calcineurin B-binding helical domain 
(residues 348ﾝ368),  a calmodulin binding region (res-
idues 390ﾝ414),  and an autoinhibitory loop (residues 
468ﾝ490).  The gene for mammalian calcineurin B 
encodes a protein of 170 amino acids containing four 
Ca2＋-binding EF-hand motifs [87] (Fig.  4). 
Calcineurin B consists of two Ca2＋-binding domains, 
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N-ter. C-ter.
1
1
170
Calcineurin B
Calcineurin A N-ter. C-ter.
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521
501
57ﾝ58 kDa
48 kDa
45 kDa
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Ca2+-binding EF-hand Catalytic domain Calcineurin B binding domain
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C
Fig. 4　　Schematic representation of structure of calcineurin subunits and calpain-dependent truncation of calcineurin A.  A, 
Calcineurin B protein,  the regulatory subunit,  encoded by the mammalian calcineurin B gene.  It has four Ca2＋-binding EF-hand 
motifs ; B,  Calcineurin A,  the catalytic subunit.  The linear peptide sequence of the calcineurin A subunit is shown,  indicating the 
catalytic domain (residues 70ﾝ328),  the calcineurin B binding domain (residues 348ﾝ362),  the calmodulin binding domain (residues 391ﾝ
414),  and the autoinhibitory domain (residues 468ﾝ490) ; C,  Three calpain-dependent truncated forms of calcineurin A in vitro.  Analysis 
by MALDI-TOF has shown that the N-terminal remaining fragments are 1ﾝ392 residues,  1ﾝ424 residues,  and 1ﾝ501 residues,  which 
correspond to 45,  48,  and 57ﾝ58 kDa truncated calcineurin A.
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domain 1 (residues 1ﾝ84) and domain 2 (residues 86ﾝ
169),  which are arranged linearly along its binding 
domain in calcineurin A.  Each domain contains two 
Ca2＋-binding EF-hand motifs that are similar to those 
of calmodulin.
Ca2＋-dependent and Calpain-dependent 
Activation of Calcineurin
　　As a serine/threonine protein phosphatase,  calci-
neurin acts as an eﬀ ector of Ca2＋ signaling by regu-
lating the phosphorylation state of proteins and par-
ticipates in a number of cellular processes,  including 
immune system responses [1,  69,  88ﾝ92],  cardiac 
hypertrophy [93ﾝ101],  neuronal and muscle develop-
ment [102,  103],  the second messenger cAMP path-
way [89,  104],  Na/K ion transportation in nephron 
[105],  and cell cycle regression in lower eukaryotes 
[106].
　　Full activation of the phosphatase activity 
requires both the binding of Ca2＋ to calcineurin B 
and Ca2＋-dependent binding of calmodulin to calcineu-
rin A [1,  2,  69,  109].  In the inactive state,  the 
autoinhibitory domain sterically blocks the active 
site.  When the calcium concentration increases,  cal-
cium and calmodulin bind to their binding sites on 
heterodimeric calcineurin and trigger a conforma-
tional shift,  resulting in the release of the autoinhibi-
tory domain from the catalytic active site.  The pro-
posed Ca2＋/calmodulin-triggered activation of 
calcineurin takes place during physiological condi-
tions and is reversible (Fig.  5).
　　In addition to the conventional activation pathway, 
studies have suggested that calcineurin activation is 
also protease-dependent.  Irreversible proteolytic 
activation of calcineurin occurs in vitro and in vivo. 
Proteases such as calpain,  trypsin,  and chymotryp-
sin C have been reported to cleave calcineurin A 
in vitro [63,  110ﾝ113].  This proteolytic truncation 
of calcineurin A is site-limited,  as only the carboxy-
terminus of the molecule containing the calmodulin-
binding domain and the autoinhibitory domain can be 
readily cleaved by proteases [112,  114].  The 
NH2-terminal two-thirds of the molecule,  which com-
prise the phosphatase catalytic domain and calcineu-
rin B-binding domain,  are resistant to proteolysis 
[112].  Proteolytic modiﬁ cation removes the regula-
tory domain of calcineurin A and changes the phos-
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Ca2+/Calmodulin
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Calcineurin
Ca2+
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cleavage
Calpain dependent
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Neuron myocardium
Excitatory delayed-
neuronal cell death
Ca2+ dependent disorders:
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Myocardial Hypertrophy
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Fig. 5　　Schematic representation of calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.  Under 
physiological conditions,  calcineurin activity is regulated by Ca2＋/calmodulin in a reversible manner.  Under some pathological conditions, 
such as Ca2＋-mediated disorders,  calcineurin activity is increased by overactivated calpain.  Calpain-mediated irreversible activation of 
calcineurin is correlated with the major pathology,  the number of neuroﬁ brillary tangles in human Alzheimer's disease brains,  and the 
myocardial hypertrophy in human.
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phatase to its constitutively active form,  which no 
longer requires calcium and calmodulin for activation 
[112,  115].
　　Calpain and calcineurin are both Ca2＋-regulated 
proteins in the brain,  in which the calcineurin-medi-
ated signaling pathway is regulated by calpain. 
Increased calpain activity is able to cleave cain/cabin 
1,  an endogenous calcineurin inhibitor [116].  When 
cleaved,  cain/cabin 1 can no longer inhibit calcineu-
rin.  Evidence from Jurkat cells has shown that cleav-
age of cain/cabin 1 by calpain is a necessary step in 
calcineurin-mediated cell death.  In addition,  calci-
neurin A has been shown to be a speciﬁ c substrate of 
calpain in neuronal cultures and in mouse hippocam-
pus [63].  The calpain-mediated post-translational 
modiﬁ cation made the protein phosphatase constitu-
tively active.  Mass spectrometry analysis by 
MALDI-TOF has identiﬁ ed several cleavage sites in 
calcineurin A after in vitro cleavage by calpain.  The 
N-terminal remaining fragments are 1ﾝ392 residues, 
1ﾝ424 residues,  and 1ﾝ501 residues,  which corre-
spond to 45,  48,  and 57 kDa truncated forms of cal-
cineurin A.  The calpain-cleaved 45 kDa form of cal-
cineurin A does not include the calmodulin-binding 
domain or the autoinhibitory domain,  while the 
48 kDa truncated form contains the cleaved 
C-terminal region of the calmodulin-binding 
domain. Both products lack the autoinhibitory domain. 
The 57 kDa truncated calcineurin A is a result of 
cleavage at the C-terminal side of the autoinhibitory 
domain,  and includes the calcineurin B-binding, 
calmodulin-binding,  and autoinhibitory domains. 
Studies have shown that the calpain-cleaved 48 kDa 
and 45 kDa truncations of calcineurin A have full 
enzyme activity and thus are constitutively active 
forms.  In transfected HEK cells,  these two 
N-terminal truncated forms can initiate calcineurin-
mediated NFAT (nuclear factor of activated T-cell) 
gene transcription.  In cultured hippocampal neurons, 
overexpressing an adenoviral-based 48 kDa trunca-
tion of calcineurin A induces caspase activation and 
neuronal cell death.  Moreover,  calpain activation 
and the production of 45ﾝ48 kDa truncation of calci-
neurin A is associated with glutamate-induced neuro-
excitotoxicity in cultures of hippocampal neurons and 
kainate-induced neuroexcitotoxicity in mouse hippo-
campus.
Calcineurin Inhibitors
　　Calcineurin activity can be inhibited by its autoin-
hibitory peptide,  which is a 26-residue peptide that 
interacts with the catalytic domain of the A subunit. 
This peptide blocks calcineurin activity with an IC50 
of 5 μM but lacks the ability to permeate the cell 
membrane [114].  It has been shown that fusing this 
peptide with 11R,  the protein transduction domain 
that is used to introduce the calpain inhibitory pep-
tide CS through the cell membrane,  also allows the 
autoinhibitory peptide to go through the cell mem-
brane [117].  Application of the 11R autoinhibitory 
peptide into cultured neurons eﬃ  ciently inhibits the 
phosphatase activity of calcineurin,  calcineurin-
dependent NFAT nuclear translocation,  and NFAT-
dependent promoter activity in vivo.  Applying the 
peptide at a 50 μM concentration provides neuropro-
tection on glutamate-induced excitatory cell death 
involving a calcineurin-mediated mechanism.
　　Based on the 11R transduction domain,  a high-
aﬃ  nity calcineurin-binding peptide has been devel-
oped by the fusion of this peptide with VIVIT,  the 
calcineurin docking motif of NFAT [118,  119].  The 
11R-VIVIT interferes selectively with the interac-
tion between calcineurin and its substrate NFAT, 
blocking activation and expression of NFAT-
dependent cytokine genes without aﬀ ecting the 
expression of other cytokines that require calcineu-
rin but not NFAT.  The substrate-selective inhibitory 
peptide has an advantage over other calcineurin 
inhibitors in target speciﬁ city,  which indiscrimi-
nately blocks all signaling downstream of the phos-
phatase.  Data have shown that this 11R-VIVIT pep-
tide provides immunosuppression for fully 
mismatched islet allografts in mice without aﬀ ecting 
insulin secretion [119].  A more recent study has 
demonstrated that this peptide is capable of prevent-
ing the development of pressure-overload cardiac 
hypertrophy in a rat model.  This speciﬁ c NFAT 
inhibitor peptide can decrease the ratio of rat heart 
weight to body weight,  the size of cardiac myocytes, 
and the serum brain natriuretic peptide and atrial 
natriuretic peptide levels during the pressure-over-
load hypertrophic response [120].
　　Immunosuppressant drugs cyclosporine A (CsA) 
and FK506 have long been known as speciﬁ c potent 
inhibitors of calcineurin [121].  They are fungal-
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derived compounds that require binding to their cog-
nate intracellular immunophilins (cyclophilin A for 
cyclosporine A and FKBP12 for FK506) prior to 
inhibiting calcineurin activity.  The cyclosporine A/
cyclophilin A or FK506/FKBP12 complex binds to a 
variety of sites in calcineurin,  including the 
N-terminus of the calcineurin B binding helix,  the 
calcineurin B-subunit,  and the catalytic domain of 
calcineurin [121].
　　In addition to synthetic and natural inhibitors, 
calcineurin protein phosphatase activity is also known 
to be potentially inhibited by a number of endogenous 
cellular proteins,  such as protein kinase A anchoring 
protein (AKAP79),  cain/cabin 1,  calcineurin homolo-
gous protein (CHP),  and the calcipressin family of 
proteins [122ﾝ128].  In rat hippocampal neurons, 
calcineurin and the regulatory subunit of protein 
kinase A colocalize via AKAP79,  which contains a 
domain homologous to FKBP that is predicted to be 
a calcineurin binding domain [122].  Cain/cabin 1 is 
a 2220-residue phosphoprotein that inhibits calcinu-
erin phosphatase activity in a noncompetitive fashion 
[123].  In cells,  the overexpression of CHP inhibits 
calcineurin phosphatase activity by 50ｵ and presents 
in a dose-dependent manner.  As the major member of 
the calcipressin family,  calcipressin 1,  also known as 
Down Syndrome Critical Region 1 (DSCR1),  is 
expressed in diverse cell types and tissues,  including 
heart/cardiac muscle,  striate muscle,  brain/neuronal 
cells,  and T-cells [127,  129ﾝ135].  Calcipressin 1 
binds to calcineurin at or near the active site and 
negatively regulates calcineurin phosphatase activity. 
Its biological roles include protection against calcium-
mediated oxidative stress,  cardiac hypertrophy, 
VEGF-mediated signaling during angiogenesis,  and 
the formation of aggresomes in Alzheimer’s disease 
[132,  136ﾝ141].
Calpain-calcineurin Signaling in 
Calcium-dependent Disorders
Calpain-calcineurin signaling in Alzheimer’s 
disease.　 Alzheimer’s disease is a progressive and 
irreversible neurodegenerative disorder character-
ized by cognitive,  memory,  and behavioral impair-
ments [142,  143].  The disease process involves the 
degeneration of synapses and neurons,  particularly 
in the hippocampus and neocortex.  The histological 
hallmarks of these brain regions of patients with 
Alzheimer’s include extracellular deposits of 
ｹ-amyloid in neuritic plaques,  intracellular neuroﬁ -
brillary tangles consisting of abnormally hyperphos-
phorylated aggregates of the microtubule-associated 
protein tau,  and selective neuronal loss.  Although 
the molecular pathogenesis of Alzheimer’s disease is 
not fully understood,  dysregulation of calcium 
homeostasis is believed to play an important role in 
neurodegeneration.  Evidence has shown that the dis-
turbance of calcium homeostasis causes widespread 
activation of calpain in the brain in Alzheimer’s dis-
ease ; an abnormal increase in calpain activity could 
be a potential molecular basis for neuronal degenera-
tion [144,  145].  In Alzheimer’s disease,  the ratio of 
activated calpain I to its latent precursor isoform in 
the neocortex is threefold than that in normal indi-
viduals.  In surviving cells,  persistent calpain activa-
tion in the brain in Alzheimer’s disease strongly cor-
relates with neuroﬁ brillary pathology and with the 
extent of decline in levels of secreted amyloid pre-
cursor protein in the brain [144,  145].  Moreover, 
researchers have observed that the overactivation of 
calpain I in the brain in Alzheimer’s disease contrib-
utes to proteolytically activated calcineurin,  and that 
the calpain-mediated activation of calcineurin is cor-
related with major brain pathology and the number of 
neuroﬁ brillary tangles (NFTs) in human Alzheimer’s 
brains [146].  Analysis by mass spectrometry has 
indicated that in the brain with Alzheimer’s disease, 
calpain I cleaved oﬀ  C-terminal 20 amino acids from 
60 kDa full-length to 57 kDa truncated calcineurin A 
at lysine 501,  a position C-terminal to the autoinhibi-
tory domain.  Similar to the wild type,  the 57 kDa 
truncated calcineurin A still requires Ca2＋/calmodu-
lin for its phosphatase activity,  but this phosphatase 
activity is remarkably activated upon truncation. 
Calpain I-mediated truncation and activation of calci-
neurin are correlated with the numbers of NFTs but 
not with that of ｹ-amyloid plaques.  This ﬁ nding 
revealed a critical role of dysregulated calpain-calci-
neurin signaling resulting from the disturbance of 
calcium homeostasis in neuroﬁ brillary degeneration 
in Alzheimer’s disease (Fig.  5).
　　Calpain-calcineurin signaling in myocardial 
hypertrophy and ischemic myocardium.　 While 
the hypertrophic response is initially a compensatory 
mechanism that augments cardiac output,  sustained 
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hypertrophy can lead to dilated cardiomyopathy, 
heart failure,  and sudden death.  The calcineurin-
mediated transcriptional pathway is crucially involved 
in the pathogenesis of cardiac hypertrophy [93,  147
ﾝ149].  A variety of hypertrophic stimuli,  such as 
angiotensin II,  phenylephrine,  and endothelin-1,  lead 
to an elevation of intracellular Ca2＋ and subsequent 
activation of calcineurin,  which leads to dephosphor-
ylation of the nuclear transcription factor NF-ATc 
(nuclear factor of activated T-cells),  resulting in the 
induction of genes typical of cardiac hypertrophy. 
Calpain-induced activation of calcineurin has recently 
been observed in hypertrophied myocardium both in 
vitro and in vivo [150].  In an animal model of myo-
cardial hypertrophy,  stimulation of rat cardiomyo-
cytes with angiotensin II for 24 h causes a signiﬁ cant 
increase in calpain activity and calpain-mediated pro-
teolysis of calcineurin A.  Proteolysis of calcineurin 
A by calpain in angiotensin II-stimulated cardiomyo-
cytes produces a 48 kDa N-terminal fragment (resi-
dues 1ﾝ424),  which lacks the autoinhibitory domain 
and matches exactly the N-terminal truncation of cal-
cineurin A found in in vitro digestion by m-calpain 
[63].  Without the autoinhibitory domain,  the trun-
cated calcineurin A is constitutively nuclear and 
active,  even after removal of the hypertrophic stimu-
lus.  The 48 kDa N-terminal truncated form of calci-
neurin A has been found in vivo in human hypertro-
phied myocardium [150].  In addition to myocardial 
hypertrophy,  studies have shown that during isch-
emia and reperfusion,  there is increased inﬂ ux of 
Ca2＋ into the cells,  which can activate u-calpain and 
m-calpain [151,  152].  Rat heart tissues that experi-
enced 30 min ischemia followed by 30 min reperfusion 
displayed increased calpain activity and m-calpain-
mediated degradation of full-length calcineurin A.  In 
that model,  calpain-mediated cleavage created a 
46 kDa truncated calcineurin A and caused increased 
calcineurin phosphotase activity in general [153]. 
This suggests that calpain-calcineurin signaling might 
be a critical contributor to the pathogenesis of rat 
ischemic myocardium (Fig.  5).
Concluding Remarks
　　Calpain-mediated limited proteolysis has emerged 
as a key post-translational mechanism that regulates 
a large number of intracellular proteins.  Tight regu-
lation of calpain activity could potentially control 
substrate function,  which may be crucial to cellular 
pathophysiological processes of some Ca2＋-dependent 
disorders (Fig.  5).  Recent substantial evidence has 
demonstrated that calpain-calcineurin signaling is 
potentially associated with several Ca2＋-dependent 
disorders,  including Alzheimer’s disease and cardiac 
hypertrophy,  providing a better understanding of the 
pathogenesis of these diseases.  Abnormal calpain 
activity can lead to cleavage of calcineurin,  resulting 
in calcineurin phosphatase overactivation,  which 
could initiate mitochondrial dysfunction and further 
the mitochondria-dependent cell death pathway [154ﾝ
157].  In addition,  calpain-mediated cleavage of calci-
neurin activates the protein phosphatase,  resulting in 
cardiac hypertrophy.  Inhibition of calcineurin activ-
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Table 2　　Cell membrane permeable 11R fusion peptides and their properties
Peptide name Inhibitory Target Role of the peptide Reference
Eleven
Arginine-Calpastatin
Peptide (11R-CS)
Calpains Inhibition of calpain auto-cleavage (IC50, 
0.51 µM),  calpain-mediated cleavage of 
calcineurin (50 µM),  and glutamate-induced 
neuroexcitotoxicity (50 µM)
62, 63, 64
11R-auto-inhibitory
Peptide
Calcineurin Inhibition of alcineurin-dependent NFAT nuclear 
translocation,  NFAT-dependent promoter 
activity,  and glutamate-induced neuro-
excitotoxicity (50 µM)
117
11R-VIVIT the
NFAT-calcineurin
interaction
Inhibition of activation and expression of NFAT-
dependent cytokine genes,  immunosuppression 
of fully mismatched islet allografts in mice, 
prevention of rat development of pressure-
overload cardiac hypertrophy.
119, 120
11R-VEET NA A control peptide of 11R-VIVIT 119, 120
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ity in transgenic mice expressing activated calcineu-
rin by administration of the immunosuppressant CyA 
blocks the development of hypertrophy [158ﾝ162]. 
Thus,  calpain inhibitors,  which block calpain-depen-
dent calcineurin activation,  may merit investigation 
as potential therapeutics for certain forms of heart 
and neurodegenerative disease.  Further biochemical 
and physiological experiments will be necessary to 
establish their role,  both in vitro and in vivo,  in the 
inhibition of the calpain-calcineurin pathway,  using 
11R-fused member-permeable peptide inhibitors 
(Table 2) in those Ca2＋-related diseases.
Acknowledgments.  This work was supported by a grant-in-aid for 
scientiﬁ c research from the Ministry of Education,  Science,  Sports and 
Culture of Japan.  We would like to thank Isabelle Baconguis and Amy 
Gleichman for reading the manuscript.
References
　1. Klee CB,  Ren H and Wang X : Regulation of the calmodulin-stim-
ulated protein phosphatase,  calcineurin.  J Biol Chem (1998) 
273 : 13367ﾝ13370.
 2. Stewart AA,  Ingebritsen TS,  Manalan A,  Klee CB and Cohen 
P : Discovery of a Ca2＋-and calmodulin-dependent protein phos-
phatase : probable identity with calcineurin (CaM-BP80).  FEBS 
Lett (1982) 137 : 80ﾝ84.
 3. Arthur JS,  Elce JS,  Hegadorn C,  Williams K and Greer 
PA : Disruption of the murine calpain small subunit gene, 
Capn4 : calpain is essential for embryonic development but not 
for cell growth and division.  Mol Cell Biol (2000) 20 : 4474ﾝ4481.
 4. Zhang W,  Lane RD and Mellgren RL : The major calpain iso-
zymes are long-lived proteins.  Design of an antisense strategy for 
calpain depletion in cultured cells.  J Biol Chem (1996) 
271 : 18825ﾝ18830.
 5. Patel YM and Lane MD : Mitotic clonal expansion during preadi-
pocyte diﬀ erentiation : calpain-mediated turnover of p27.  J Biol 
Chem (2000) 275 : 17653ﾝ17660.
 6. Grynspan F,  Griﬃ  n WB,  Mohan PS,  Shea TB and Nixon 
RA : Calpains and calpastatin in SH-SY5Y neuroblastoma cells 
during retinoic acid-induced diﬀ erentiation and neurite out-
growth : comparison with the human brain calpain system.  J 
Neurosci Res (1997) 48 : 181ﾝ191.
 7. Shiraha H,  Glading A,  Gupta K and Wells A : IP-10 inhibits epi-
dermal growth factor-induced motility by decreasing epidermal 
growth factor receptor-mediated calpain activity.  J Cell Biol (1999) 
146 : 243ﾝ254.
 8. Glading A,  Uberall F,  Keyse SM,  Lauﬀ enburger DA and Wells 
A : Membrane proximal ERK signaling is required for M-calpain 
activation downstream of epidermal growth factor receptor signal-
ing.  J Biol Chem (2001) 276 : 23341ﾝ23348.
 9. Kulkarni S,  Saido TC,  Suzuki K and Fox JE : Calpain mediates 
integrin-induced signaling at a point upstream of Rho family mem-
bers.  J Biol Chem (1999) 274 : 21265ﾝ21275.
 10. Zhang W,  Lu Q,  Xie ZJ and Mellgren RL : Inhibition of the growth 
of WI-38 ﬁ broblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazo-
methyl ketone : evidence that cleavage of p53 by a calpain-like 
protease is necessary for G1 to S-phase transition.  Oncogene 
(1997) 14 : 255ﾝ263.
 11. Santella L,  Kyozuka K,  Hoving S,  Munchbach M,  Quadroni M, 
Dainese P,  Zamparelli C,  James P and Carafoli E : Breakdown 
of cytoskeletal proteins during meiosis of starﬁ sh oocytes and 
proteolysis induced by calpain.  Exp Cell Res (2000) 259 : 117ﾝ
126.
 12. Schollmeyer JE : Calpain II involvement in mitosis.  Science (1988) 
240 : 911ﾝ913.
 13. Carafoli E and Molinari M : Calpain : a protease in search of a 
function? Biochem Biophys Res Commun (1998) 247 : 193ﾝ203.
 14. Ono Y,  Shimada H,  Sorimachi H,  Richard I,  Saido TC, 
Beckmann JS,  Ishiura S and Suzuki K : Functional defects of a 
muscle-speciﬁ c calpain,  p94,  caused by mutations associated 
with limb-girdle muscular dystrophy type 2A.  J Biol Chem (1998) 
273 : 17073ﾝ17078.
 15. Wang KKW : Calpain and caspase : can you tell the diﬀ erence? 
Trends Neurosci (2000) 23 : 20ﾝ26.
 16. Horikawa Y,  Oda N,  Cox NJ,  Li X,  Orho-Melander M,  Hara M, 
Hinokio Y,  Lindner TH,  Mashima H,  Schwarz PE,  del Bosque-
Plata L,  Horikawa Y,  Oda Y,  Yoshiuchi I,  Colilla S,  Polonsky 
KS,  Wei S,  Concannon P,  Iwasaki N,  Schulze J,  Baier LJ, 
Bogardus C,  Groop L,  Boerwinkle E,  Hanis CL and Bell 
GI : Genetic variation in the gene encoding calpain-10 is associ-
ated with type 2 diabetes mellitus.  Nat Genet (2000) 26 : 163ﾝ
175.
 17. Richard I,  Roudaut C,  Saenz A,  Pogue R,  Grimbergen JE, 
Anderson LV,  Beley C,  Cobo AM,  de Diego C,  Eymard B, 
Gallano P,  Ginjaar HB,  Lasa A,  Pollitt C,  Topaloglu H, 
Urtizberea JA,  de Visser M,  van der Kooi A,  Bushby K,  Bakker E, 
Lopez de Munain A,  Fardeau M and Beckmann 
JS : Calpainopathy-a survey of mutations and polymorphisms.  Am 
J Hum Genet (1999) 64 : 1524ﾝ1540.
 18. Vanderklish PW and Bahr BA : The pathogenic activation of cal-
pain : a marker and mediator of cellular toxicity and disease 
states.  Int J Exp Pathol (2000) 81 : 323ﾝ239.
 19. Melloni E and Pontremoli S : The calpains.  Trends Neurosci (1989) 
12 : 438ﾝ444.
 20. Goll DE,  Thompson VF,  Li H,  Wei W and Cong J : The calpain 
system.  Physiol Rev (2003) 83 : 731ﾝ801.
 21. Suzuki K,  Hata S,  Kawabata Y and Sorimachi H : Structure, 
activation,  and biology of calpain.  Diabetes (2004) 53 : S12ﾝ18.
 22. Moldoveanu T,  Campbell RL,  Cuerrier D and Davies PL : Crystal 
structures of calpain-E64 and -leupeptin inhibitor complexes 
reveal mobile loops gating the active site.  J Mol Biol (2004) 
343 : 1313ﾝ1326.
 23. Reverter D,  Strobl S,  Fernandez-Catalan C,  Sorimachi H, 
Suzuki K and Bode W : Structural basis for possible calcium-
induced activation mechanisms of calpains.  Biol Chem (2001) 
382 : 753ﾝ766.
 24. Newton AC and Johnson JE : Protein kinase C : a paradigm for 
regulation of protein function by two membrane-targeting modules. 
Biochim Biophys Acta (1998) 1376 : 155ﾝ172.
 25. Tompa P,  Emori Y,  Sorimachi H,  Suzuki K and Friedrich 
P : Domain III of calpain is a Ca2＋-regulated phospholipid-binding 
domain.  Biochem Biophys Res Commun (2001) 280 : 1333ﾝ1339.
 26. Babu YS,  Bugg CE and Cook WJ : Structure of calmodulin 
reﬁ ned at 2.2 A resolution.  J Mol Biol (1988) 204 : 191ﾝ204.
 27. Cygler M,  Grochulski P and Blanchard H : Crystallization and 
structural details of Ca(2＋)-induced conformational changes in 
the EF-hand domain VI of calpain.  Methods Mol Biol (2002) 
133Calpain-calcineurin Signaling in the Pathogenesis of Calcium-dependent DisorderJune 2007
11
Wu et al.: Calpain-calcineurin signaling in the pathogenesis of calcium-depe
Produced by The Berkeley Electronic Press, 2007
172 : 243ﾝ260.
 28. Minami Y,  Emori Y,  Kawasaki H and Suzuki K : E-F hand struc-
ture-domain of calcium-activated neutral protease (CANP) can 
bind Ca2＋ ions.  J Biochem (Tokyo) (1987) 101 : 889ﾝ895.
 29. Hosﬁ eld CM,  Elce JS,  Davies PL and Jia Z : Crystal structure of 
calpain reveals the structural basis for Ca(2＋)-dependent prote-
ase activity and a novel mode of enzyme activation.  EMBO J 
(1999) 18 : 6880ﾝ6889.
 30. Strobl S,  Fernandez-Catalan C,  Braun M,  Huber R,  Masumoto H, 
Nakagawa K,  Irie A,  Sorimachi H,  Bourenkow G,  Bartunik H, 
Suzuki K and Bode W : The crystal structure of calcium-free 
human m-calpain suggests an electrostatic switch mechanism for 
activation by calcium.  Proc Natl Acad Sci USA (2000) 97 : 588ﾝ
592.
 31. Blanchard H,  Grochulski P,  Li Y,  Arthur JS,  Davies PL,  Elce 
JS and Cygler M : Structure of a calpain Ca(2＋)-binding domain 
reveals a novel EF-hand and Ca(2＋)-induced conformational 
changes.  Nat Struct Biol (1997) 4 : 532ﾝ538.
 32. Hosﬁ eld CM,  Ye Q,  Arthur JS,  Hegadorn C,  Croall DE,  Elce JS 
and Jia Z : Crystallization and X-ray crystallographic analysis of 
m-calpain,  a Ca2＋-dependent protease.  Acta Crystallogr D Biol 
Crystallogr (1999) 55(Pt 8) : 1484ﾝ1486.
 33. Lin GD,  Chattopadhyay D,  Maki M,  Wang KK,  Carson M,  Jin L, 
Yuen PW,  Takano E,  Hatanaka M,  DeLucas LJ and Narayana 
SV : Crystal structure of calcium bound domain VI of calpain at 1.9 
A resolution and its role in enzyme assembly,  regulation,  and 
inhibitor binding.  Nat Struct Biol (1997) 4 : 539ﾝ547.
 34. Reverter D,  Sorimachi H and Bode W : The structure of calcium-
free human m-calpain : implications for calcium activation and 
function.  Trends Cardiovasc Med (2001) 11 : 222ﾝ229.
 35. Alexa A,  Bozoky Z,  Farkas A,  Tompa P and Friedrich 
P : Contribution of distinct structural elements to activation of 
calpain by Ca2＋ ions.  J Biol Chem (2004) 279 : 20118ﾝ20126.
 36. Moldoveanu T,  Hosﬁ eld CM,  Jia Z,  Elce JS and Davies 
PL : Ca(2＋)-induced structural changes in rat m-calpain revealed 
by partial proteolysis.  Biochim Biophys Acta (2001) 1545 : 245ﾝ
254.
 37. Moldoveanu T,  Hosﬁ eld CM, Lim D,  Elce JS,  Jia Z and Davies 
PL : A Ca(2＋) switch aligns the active site of calpain.  Cell (2002) 
108 : 649ﾝ660.
 38. Baki A,  Tompa P,  Alexa A,  Molnar O and Friedrich P : Autolysis 
parallels activation of mu-calpain.  Biochem J (1996) 318 : 897ﾝ
901.
 39. Cong J,  Goll DE,  Peterson AM and Kapprell HP : The role of 
autolysis in activity of the Ca2＋-dependent proteinases (mu-calpain 
and m-calpain).  J Biol Chem (1989) 264 : 10096ﾝ10103.
 40. Elce JS,  Davies PL,  Hegadorn C,  Maurice DH and Arthur 
JS : The eﬀ ects of truncations of the small subunit on m-calpain 
activity and heterodimer formation.  Biochem J (1997) 
326(Pt 1) : 31ﾝ38.
 41. Elce JS,  Hegadorn C and Arthur JS : Autolysis : Ca2＋ require-
ment,  and heterodimer stability in m-calpain.  J Biol Chem (1997) 
272 : 11268ﾝ11275.
 42. Blanchard H,  Grochulski P,  Li Y,  Arthur JS,  Davies PL,  Elce 
JS and Cygler M : Structure of a calpain Ca(2＋)-binding domain 
reveals a novel EF-hand and Ca(2＋)-induced conformational 
changes.  Nat Struct Biol (1997) 4 : 532ﾝ538.
 43. Guttmann RP,  Elce JS,  Bell PD,  Isbell JC and Johnson 
GV : Oxidation inhibits substrate proteolysis by calpain I but not 
autolysis.  J Biol Chem (1997) 272 : 2005ﾝ2012.
 44. Imajoh S,  Kawasaki H and Suzuki K : Limited autolysis of cal-
cium-activated neutral protease (CANP) : reduction of the Ca2＋
-requirement is due to the NH2-terminal processing of the large 
subunit.  J Biochem (Tokyo) (1986) 100 : 633ﾝ642.
 45. Molinari M,  Anagli J and Carafoli E : Ca(2＋)-activated neutral 
protease is active in the erythrocyte membrane in its nonauto-
lyzed 80-kDa form.  J Biol Chem (1994) 269 : 27992ﾝ27995.
 46. Suzuki K and Sorimachi H : A novel aspect of calpain activation. 
FEBS Lett (1998) 433 : 1ﾝ4.
 47. Suzuki K,  Tsuji S and Ishiura S : Eﬀ ect of Ca2＋ on the inhibition 
of calcium-activated neutral protease by leupeptin,  antipain and 
epoxysuccinate derivatives.  FEBS Lett (1981) 136 : 119ﾝ122.
 48. Sorimachi H and Suzuki K : The structure of calpain.  J Biochem 
(Tokyo) (2001) 129 : 653ﾝ664.
 49. Wendt A,  Thompson VF and Goll DE : Interaction of calpastatin 
with calpain : a review.  Biol Chem (2004) 385 : 465ﾝ472.
 50. Todd B,  Moore D,  Deivanayagam CC,  Lin GD,  Chattopadhyay D, 
Maki M,  Wang KK and Narayana SV : A structural model for the 
inhibition of calpain by calpastatin : crystal structures of the 
native domain VI of calpain and its complexes with calpastatin 
peptide and a small molecule inhibitor.  J Mol Biol (2003) 
328 : 131ﾝ146.
 51. Imajoh S and Suzuki K : Reversible interaction between Ca2＋
-activated neutral protease (CANP) and its endogenous inhibitor. 
FEBS Lett (1985) 187 : 47ﾝ50.
 52. Otsuka Y and Goll DE : Puriﬁ cation of the Ca2＋-dependent pro-
teinase inhibitor from bovine cardiac muscle and its interaction 
with the millimolar Ca2＋-dependent proteinase.  J Biol Chem 
(1987) 262 : 5839ﾝ5851.
 53. Kapprell HP and Goll DE : Eﬀ ect of Ca2＋on binding of the cal-
pains to calpastatin.  J Biol Chem (1989) 264 : 17888ﾝ17896.
 54. Emori Y,  Kawasaki H,  Imajoh S,  Minami Y and Suzuki K : ll four 
repeating domains of the endogenous inhibitor for calcium-depen-
dent protease independently retain inhibitory activity.  Expression 
of the cDNA fragments in Escherichia coli.  J Biol Chem (1988) 
263 : 2364ﾝ2370.
 55. Takano E,  Maki M,  Mori H,  Hatanaka M,  Marti T,  Titani K, 
Kannagi R,  Ooi T and Murachi T : Pig heart calpastatin : identiﬁ -
cation of repetitive domain structures and anomalous behavior in 
polyacrylamide gel electrophoresis.  Biochemistry (1988) 27 : 1964
ﾝ1972.
 56. Maki M,  Takano E,  Mori H,  Sato A,  Murachi T and Hatanaka 
M : All four internally repetitive domains of pig calpastatin pos-
sess inhibitory activities against calpains I and II.  FEBS Lett 
(1987) 223 : 174ﾝ180.
 57. Bandyopadhyay J,  Lee J and Bandyopadhyay A : Regulation of 
calcineurin,  a calcium/calmodulin-dependent protein phospha-
tase,  in C.  elegans.  Mol Cells (2004) 18 : 10ﾝ16.
 58. Maki M,  Bagci H,  Hamaguchi K,  Ueda M,  Murachi T and 
Hatanaka M : Inhibition of calpain by a synthetic oligopeptide cor-
responding to an exon of the human calpastatin gene.  J Biol 
Chem (1989) 264 : 18866ﾝ18869.
 59. Eto A,  Akita Y,  Saido TC,  Suzuki K and Kawashima S : The role 
of the calpain-calpastatin system in thyrotropin-releasing hor-
mone-induced selective down-regulation of a protein kinase C 
isozyme,  nPKC epsilon,  in rat pituitary GH4C1 cells.  J Biol 
Chem (1995) 270 : 25115ﾝ25120.
 60. Betts R,  Weinsheimer S,  Blouse GE and Anagli J : Structural 
determinants of the calpain inhibitory activity of calpastatin pep-
tide B27-WT.  J Biol Chem (2003) 278 : 7800ﾝ7809.
 61. Matsushita M and Matsui H : Protein transduction technology.  J 
Mol Med (2005) 83 : 324ﾝ328.
134 Acta Med.  Okayama　Vol.  61,  No.  3Wu et al.
12
Acta Medica Okayama, Vol. 61 [2007], Iss. 3, Art. 1
http://escholarship.lib.okayama-u.ac.jp/amo/vol61/iss3/1
 62. Wu HY,  Tomizawa K,  Matsushita M,  Lu YF,  Li ST and Matsui 
H : Poly-arginine-fused calpastatin peptide,  a living cell mem-
brane-permeable and speciﬁ c inhibitor for calpain.  Neurosci Res 
(2003) 47 : 131ﾝ135.
 63. Wu HY,  Tomizawa K,  Oda Y,  Wei FY,  Lu YF,  Matsushita M,  Li 
ST,  Moriwaki A and Matsui H : Critical role of calpain-mediated 
cleavage of calcineurin in excitotoxic neurodegeneration.  J Biol 
Chem (2004) 279 : 4929ﾝ4940.
 64. Wu HY,  Yuen EY,  Lu YF,  Matsushita M,  Matsui H,  Yan Z and 
Tomizawa K : Regulation of N-methyl-D-aspartate receptors by 
calpain in cortical neurons.  J Biol Chem (2005) 280 : 21588ﾝ
21593.
 65. Shiraha H,  Glading A,  Chou J and Jia Z : Activation of m-calpain 
(calpain II) by epidermal growth factor is limited by protein kinase 
A phosphorylation of m-calpain.  Mol Cell Biol (2002) 22 : 2716ﾝ
2727.
 66. Smith SD,  Jia Z,  Huynh KK,  Wells A and Elce JS : Glutamate 
substitutions at a PKA consensus site are consistent with inacti-
vation of calpain by phosphorylation.  FEBS Lett (2003) 542 : 115
ﾝ118.
 67. Wang KK and Yuen PW : Development and therapeutic potential 
of calpain inhibitors.  Adv Pharmacol (1997) 37 : 117ﾝ152.
 68. Wang KK and Yuen PW : Calpain inhibition : an overview of its 
therapeutic potential.  Trends Pharmacol Sci (1994) 15 : 412ﾝ419.
 69. Klee CB,  Draetta GF and Hubbard MJ : Calcineurin.  Adv 
Enzymol Relat Areas Mol Biol (1988) 61 : 149ﾝ200.
 70. Merat DL and Cheung WY : Calmodulin-dependent protein phos-
phatase : isolation of subunits and reconstitution to holoenzyme. 
Methods Enzymol (1987) 139 : 79ﾝ87.
 71. Wallace RW,  Tallant EA and Cheung WY : High levels of a heat-
labile calmodulin-binding protein (CaM-BP80) in bovine neostria-
tum.  Biochemistry (1980) 19 : 1831ﾝ1837.
 72. Ingebritsen TS,  Stewart AA and Cohen P : The protein phospha-
tases involved in cellular regulation.  6.  Measurement of type-1 
and type-2 protein phosphatases in extracts of mammalian tis-
sues ; an assessment of their physiological roles.  Eur J Biochem 
(1983)132 : 297ﾝ307.
 73. Steiner JP,  Dawson TM,  Fotuhi M,  Glatt CE,  Snowman AM, 
Cohen N and Snyder SH : High brain densities of the immu-
nophilin FKBP colocalized with calcineurin.  Nature (1992) 
358 : 584ﾝ587.
 74. Morioka M,  Nagahiro S,  Fukunaga K,  Miyamoto E and Ushio 
Y : Calcineurin in the adult rat hippocampus : diﬀ erent distribution 
in CA1 and CA3 subﬁ elds.  Neuroscience (1997) 78 : 673ﾝ684.
 75. Jiang H,  Xiong F,  Kong S,  Ogawa T,  Kobayashi M and Liu 
JO : Distinct tissue and cellular distribution of two major isoforms 
of calcineurin.  Mol Immunol (1997) 34 : 663ﾝ669.
 76. Halpain S,  Hipolito A and Saﬀ er L : Regulation of F-actin stability 
in dendritic spines by glutamate receptors and calcineurin.  J 
Neurosci (1998) 18 : 9835ﾝ9844.
 77. Sik A,  Hajos N,  Gulacsi A,  Mody I and Freund TF : The absence 
of a major Ca2＋ signaling pathway in GABAergic neurons of the 
hippocampus.  Proc Natl Acad Sci USA (1998) 95 : 3245ﾝ3250.
 78. Klee CB,  Crouch TH and Krinks MH : Calcineurin : a calcium- 
and calmodulin-binding protein of the nervous system.  Proc Natl 
Acad Sci USA (1979) 76 : 6270ﾝ6273.
 79. Klee CB and Krinks MH : Puriﬁ cation of cyclic 3’,5’-nucleotide 
phosphodiesterase inhibitory protein by aﬃ  nity chromatography on 
activator protein coupled to Sepharose.  Biochemistry (1978) 
17 : 120ﾝ126.
 80. Guerini D : Calcineurin : not just a simple protein phosphatase. 
Biochem Biophys Res Commun (1997) 235 : 271ﾝ275.
 81. Aitken A,  Cohen P,  Santikarn S,  Williams DH,  Calder AG, 
Smith A and Klee CB : Identiﬁ cation of the NH2-terminal blocking 
group of calcineurin B as myristic acid.  FEBS Lett (1982) 
150 : 314ﾝ318.
 82. Guerini D,  Krinks MH,  Sikela JM,  Hahn WE and Klee 
CB : Isolation and sequence of a cDNA clone for human calci-
neurin B,  the Ca2＋-binding subunit of the Ca2＋/calmodulin-stimu-
lated protein phosphatase DNA (1989) 8 : 675ﾝ682.
 83. Mukai H,  Chang CD,  Tanaka H,  Ito A,  Kuno T and Tanaka 
C : cDNA cloning of a novel testis-speciﬁ c calcineurin B-like pro-
tein.  Biochem Biophys Res Commun (1991) 179 : 1325ﾝ13230.
 84. Nishio H,  Matsui H,  Moia LJ,  Taketa S,  Miyamoto K,  Tokuda M, 
Itano T,  Nakahara S and Hatase O : The evidence for post-mei-
otic expression of a testis-speciﬁ c isoform of a regulatory subunit 
of calcineurin using a monoclonal antibody.  Biochem Biophys 
Res Commun (1992) 187 : 828ﾝ831.
 85. Ueki K,  Muramatsu T and Kincaid RL : Structure and expression 
of two isoforms of the murine calmodulin-dependent protein phos-
phatase regulatory subunit (calcineurin B).  Biochem Biophys Res 
Commun (1992) 187 : 537ﾝ543.
 86. Rusnak F and Mertz P : Calcineurin : form and function.  Physiol 
Rev (2000) 80 : 1483ﾝ1521.
 87. Aitken A,  Klee CB and Cohen P : The structure of the B subunit 
of calcineurin.  Eur J Biochem (1984) 139 : 663ﾝ671.
 88. Schreiber SL : Immunophilin-sensitive protein phosphatase action 
in cell signaling pathways.  Cell (1992) 70 : 365ﾝ368.
 89. Kincaid RL : The role of calcineurin in immune system responses. 
J Allergy Clin Immunol (1995) 96 : 1170ﾝ1177.
 90. Cardenas ME,  Sanfridson A,  Cutler NS and Heitman J : Signal-
transduction cascades as targets for therapeutic intervention by 
natural products.  Trends Biotechnol (1998) 16 : 427ﾝ433.
 91. Hemenway CS and Heitman J : Calcineurin.  Structure,  function, 
and inhibition.  Cell Biochem Biophys (1999) : 115ﾝ151.
 92. Crabtree GR : Calcium,  calcineurin,  and the control of transcrip-
tion.  J Biol Chem (2001) 276 : 2313ﾝ2316.
 93. Bueno OF,  van Rooij E,  Molkentin JD,  Doevendans PA and De 
Windt LJ : Calcineurin and hypertrophic heart disease : novel 
insights and remaining questions.  Cardiovasc Res (2002) 53 : 806
ﾝ821.
 94. Bueno OF,  Wilkins BJ,  Tymitz KM,  Glascock BJ,  Kimball TF, 
Lorenz JN and Molkentin JD : Impaired cardiac hypertrophic 
response in Calcineurin Abeta -deﬁ cient mice.  Proc Natl Acad 
Sci USA (2002) 99 : 4586ﾝ4591.
 95. Periasamy M : Calcineurin and the heartbeat,  an evolving story. 
J Mol Cell Cardiol (2002) 34 : 259ﾝ262.
 96. Wilkins BJ and Molkentin JD : Calcineurin and cardiac hypertro-
phy : where have we been? Where are we going? J Physiol (2002) 
541 : 1ﾝ8.
 97. Zhang W : Old and new tools to dissect calcineurin's role in pres-
sure-overload cardiac hypertrophy.  Cardiovasc Res (2002) 
53 : 294ﾝ303.
 98. Izumo S and Aoki H : Calcineurin ﾝ the missing link in cardiac 
hypertrophy.  Nat Med (1998) 4 : 661ﾝ662.
 99. Nolan GP : Cardiac development.  Transcription and the broken 
heart.  Nature (1998) 392 : 129ﾝ130.
100. Molkentin JD,  Lu JR,  Antos CL,  Markham B,  Richardson J, 
Robbins J,  Grant SR and Olson EN : A calcineurin-dependent 
transcriptional pathway for cardiac hypertrophy.  Cell (1998) 
93 : 215ﾝ228.
101. Guo L,  Nakamura K,  Lynch J,  Opas M,  Olson EN,  Agellon LB 
135Calpain-calcineurin Signaling in the Pathogenesis of Calcium-dependent DisorderJune 2007
13
Wu et al.: Calpain-calcineurin signaling in the pathogenesis of calcium-depe
Produced by The Berkeley Electronic Press, 2007
and Michalak M : Cardiac-speciﬁ c expression of calcineurin 
reverses embryonic lethality in calreticulin-deﬁ cient mouse.  J Biol 
Chem (2002) 277 : 50776ﾝ50779.
102. Antoni FA,  Palkovits M,  Simpson J,  Smith SM,  Leitch AL, 
Rosie R,  Fink G and Paterson JM : Ca2＋/calcineurin-inhibited 
adenylyl cyclase,  highly abundant in forebrain regions,  is impor-
tant for learning and memory.  J Neurosci (1998) 18 : 9650ﾝ9661.
103. Schiaﬃ  no S and Serrano A : Calcineurin signaling and neural 
control of skeletal muscle ﬁ ber type and size.  Trends Pharmacol 
Sci (2002) 23 : 569ﾝ575.
104. Antoni FA,  Smith SM,  Simpson J,  Rosie R,  Fink G and Paterson 
JM : Calcium control of adenylyl cyclase : the calcineurin connec-
tion.  Adv Second Messenger Phosphoprotein Res (1998) 32 : 153
ﾝ172.
105. Tumlin JA : Expression and function of calcineurin in the mamma-
lian nephron : physiological roles,  receptor signaling,  and ion 
transport.  Am J Kidney Dis (1997) 30 : 884ﾝ895.
106. Nanthakumar NN,  Dayton JS and Means AR : Role of Ca＋＋/
calmodulin binding proteins in Aspergillus nidulans cell cycle reg-
ulation.  Prog Cell Cycle Res (1996) 2 : 217ﾝ228.
107. Winder DG,  Mansuy IM,  Osman M,  Moallem TM and Kandel 
ER : Genetic and pharmacological evidence for a novel,  interme-
diate phase of long-term potentiation suppressed by calcineurin. 
Cell (1998) 92 : 25ﾝ37.
108. Mansuy IM,  Mayford M,  Jacob B,  Kandel ER and Bach 
ME : Restricted and regulated overexpression reveals calcineurin 
as a key component in the transition from short-term to long-term 
memory.  Cell (1998) 92 : 39ﾝ49.
109. Stemmer P and Klee CB : Serine/threonine phosphatases in the 
nervous system.  Curr Opin Neurobiol (1991) 1 : 53ﾝ64.
110. Wang KK,  Roufogalis BD and Villalobo A : Characterization of 
the fragmented forms of calcineurin produced by calpain I. 
Biochem Cell Biol (1989) 67 : 703ﾝ711.
111. Manalan AS and Klee CB : Activation of calcineurin by limited 
proteolysis.  Proc Natl Acad Sci USA (1983) 80 : 4291ﾝ4295.
112. Hubbard MJ and Klee CB : Functional domain structure of calci-
neurin A : mapping by limited proteolysis.  Biochemistry (1989) 
28 : 1868ﾝ1874.
113. Yang SA and Klee C : Study of calcineurin structure by limited 
proteolysis.  Methods Mol Biol (2002) 172 : 317ﾝ334.
114. Hashimoto Y,  Perrino BA and Soderling TR : Identiﬁ cation of an 
autoinhibitory domain in calcineurin.  J Biol Chem (1990) 
265 : 1924ﾝ1927.
115. Perrino BA,  Ng LY and Soderling TR : Calcium regulation of cal-
cineurin phosphatase activity by its B subunit and calmodulin. 
Role of the autoinhibitory domain.  J Biol Chem (1995) 270 : 340ﾝ
346.
116. Kim MJ,  Jo DG,  Hong GS,  Kim BJ,  Lai M,  Cho DH,  Kim KW, 
Bandyopadhyay A,  Hong YM,  Kim do H,  Cho C,  Liu JO,  Snyder 
SH and Jung YK : Calpain-dependent cleavage of cain/cabin1 
activates calcineurin to mediate calcium-triggered cell death. 
Proc Natl Acad Sci USA (2002) 99 : 9870ﾝ9875.
117. Terada H,  Matsushita M,  Lu YF,  Shirai T,  Li ST,  Tomizawa K, 
Moriwaki A,  Nishio S,  Date I,  Ohmoto T and Matsui H : Inhibition 
of excitatory neuronal cell death by cell-permeable calcineurin 
autoinhibitory peptide.  J Neurochem (2003) 87 : 1145ﾝ1151.
118. Aramburu J,  Yaﬀ e MB,  Lopez-Rodriguez C,  Cantley LC,  Hogan 
PG and Rao A : Aﬃ  nity-driven peptide selection of an NFAT 
inhibitor more selective than cyclosporin A.  Science (1999) 
285 : 2129ﾝ2133.
119. Noguchi H,  Matsushita M,  Okitsu T,  Moriwaki A,  Tomizawa K, 
Kang S,  Li ST,  Kobayashi N,  Matsumoto S,  Tanaka K,  Tanaka 
N and Matsui HA : new cell-permeable peptide allows successful 
allogeneic islet transplantation in mice.  Nat Med (2004) 10 : 305ﾝ
309.
120. Kuriyama M,  Matsushita M,  Tateishi A,  Moriwaki A,  Tomizawa K, 
Ishino K,  Sano S and Matsui H : A Cell-permeable NFAT Inhibitor 
Peptide Prevents Pressure-Overload Cardiac Hypertrophy.  Chem 
Biol Drug Des (2006) 67 : 238ﾝ243.
121. Liu J,  Farmer JD Jr,  Lane WS,  Friedman J,  Weissman I and 
Schreiber SL : Calcineurin is a common target of cyclophilin-
cyclosporin A and FKBP-FK506 complexes.  Cell (1991) 66 : 807ﾝ
815.
122. Coghlan VM,  Perrino BA,  Howard M,  Langeberg LK,  Hicks JB, 
Gallatin WM and Scott JD : Association of protein kinase A and 
protein phosphatase 2B with a common anchoring protein. 
Science (1995) 267 : 108ﾝ111.
123. Lai MM,  Burnett PE,  Wolosker H,  Blackshaw S and Snyder 
SH : Cain,  a novel physiologic protein inhibitor of calcineurin.  J 
Biol Chem (1998) 273 : 18325ﾝ18331.
124. Lin X,  Sikkink RA,  Rusnak F and Barber DL : Inhibition of calci-
neurin phosphatase activity by a calcineurin B homologous pro-
tein.  J Biol Chem (1999) 274 : 36125ﾝ36131.
125. Kingsbury TJ and Cunningham KW : A conserved family of calci-
neurin regulators.  Genes Dev (2000) 14 : 1595ﾝ1604.
126. Strippoli P,  Petrini M,  Lenzi L,  Carinci P and Zannotti M : The 
murine DSCR1-like (Down syndrome candidate region 1) gene 
family : conserved synteny with the human orthologous genes. 
Gene (2000) 257 : 223ﾝ232.
127. Rothermel B,  Vega RB,  Yang J,  Wu H,  Bassel-Duby R and 
Williams RS : A protein encoded within the Down syndrome criti-
cal region is enriched in striated muscles and inhibits calcineurin 
signaling.  J Biol Chem (2000) 275 : 8719ﾝ8725.
128. Rothermel BA,  Vega RB and Williams RS : The role of modula-
tory calcineurin-interacting proteins in calcineurin signaling. 
Trends Cardiovasc Med (2003) 13 : 15ﾝ21.
129. Fuentes JJ,  Pritchard MA and Estivill X : Genomic organization, 
alternative splicing,  and expression patterns of the DSCR1 (Down 
syndrome candidate region 1) gene.  Genomics (1997) 44 : 358ﾝ
361.
130. Casas C,  Martinez S,  Pritchard MA,  Fuentes JJ,  Nadal M, 
Guimera J,  Arbones M,  Florez J,  Soriano E,  Estivill X and 
Alcantara S : Dscr1,  a novel endogenous inhibitor of calcineurin 
signaling,  is expressed in the primitive ventricle of the heart and 
during neurogenesis.  Mech Dev (2001) 101 : 289ﾝ292.
131. Wang Y,  De Keulenaer GW,  Weinberg EO,  Muangman S, 
Gualberto A,  Landschulz KT,  Turi TG,  Thompson JF and Lee 
RT : Direct biomechanical induction of endogenous calcineurin 
inhibitor Down Syndrome Critical Region-1 in cardiac myocytes. 
Am J Physiol Heart Circ Physiol (2002) 283 : H533ﾝ539.
132. Lange AW,  Molkentin JD and Yutzey KE : DSCR1 gene expres-
sion is dependent on NFATc1 during cardiac valve formation and 
colocalizes with anomalous organ development in trisomy 16 
mice.  Dev Biol (2004) 266 : 346ﾝ360.
133. Yang J,  Rothermel B,  Vega RB,  Frey N,  McKinsey TA,  Olson 
EN,  Bassel-Duby R and Williams RS : Independent signals con-
trol expression of the calcineurin inhibitory proteins MCIP1 and 
MCIP2 in striated muscles.  Circ Res (2000) 87 : E61ﾝ68.
134. Ermak G,  Morgan TE and Davies KJ : Chronic overexpression of 
the calcineurin inhibitory gene DSCR1 (Adapt78) is associated 
with Alzheimer's disease.  J Biol Chem (2001) 276 : 38787ﾝ38794.
135. Ryeom S,  Greenwald RJ,  Sharpe AH and McKeon F : The 
136 Acta Med.  Okayama　Vol.  61,  No.  3Wu et al.
14
Acta Medica Okayama, Vol. 61 [2007], Iss. 3, Art. 1
http://escholarship.lib.okayama-u.ac.jp/amo/vol61/iss3/1
threshold pattern of calcineurin-dependent gene expression is 
altered by loss of the endogenous inhibitor calcipressin.  Nat 
Immunol (2003) 4 : 874ﾝ881.
136. Ermak G,  Harris CD and Davies KJ : The DSCR1 (Adapt78) iso-
form 1 protein calcipressin 1 inhibits calcineurin and protects 
against acute calcium-mediated stress damage,  including tran-
sient oxidative stress.  FASEB J (2002) 16 : 814ﾝ824.
137. Lin HY,  Michtalik HJ,  Zhang S,  Andersen TT,  Van Riper DA, 
Davies KK,  Ermak G,  Petti LM,  Nachod S,  Narayan AV,  Bhatt 
N and Crawford DR : Oxidative and calcium stress regulate 
DSCR1 (Adapt78/MCIP1) protein.  Free Radic Biol Med (2003) 
35 : 528ﾝ539.
138. van Rooij E,  Doevendans PA,  Crijns HJ,  Heeneman S,  Lips DJ, 
van Bilsen M,  Williams RS,  Olson EN,  Bassel-Duby R, 
Rothermel BA and De Windt LJ : MCIP1 overexpression sup-
presses left ventricular remodeling and sustains cardiac function 
after myocardial infarction.  Circ Res (2004) 94 : e18ﾝ26.
139. Iizuka M,  Abe M,  Shiiba K,  Sasaki I and Sato Y : Down syn-
drome candidate region 1,  a downstream target of VEGF,  partici-
pates in endothelial cell migration and angiogenesis.  J Vasc Res 
(2004) 41 : 334ﾝ344.
140. Hesser BA,  Liang XH,  Camenisch G,  Yang S,  Lewin DA, 
Scheller R,  Ferrara N and Gerber HP : Down syndrome critical 
region protein 1 (DSCR1),  a novel VEGF target gene that regu-
lates expression of inﬂ ammatory markers on activated endothelial 
cells.  Blood (2004) 104 : 149ﾝ158.
141. Ma H,  Xiong H,  Liu T,  Zhang L,  Godzik A and Zhang 
Z : Aggregate formation and synaptic abnormality induced by 
DSCR1.  J Neurochem (2004) 88 : 1485ﾝ1496.
142. LaFerla FM : Calcium dyshomeostasis and intracellular signalling 
in Alzheimer's disease.  Nat Rev Neurosci (2002) 3 : 862ﾝ872.
143. Mattson MP and Chan SL : Neuronal and glial calcium signaling 
in Alzheimer's disease.  Cell Calcium (2003) 34 : 385ﾝ397.
144. Saito K,  Elce JS,  Hamos JE and Nixon RA : Widespread activa-
tion of calcium-activated neutral proteinase (calpain) in the brain 
in Alzheimer disease : a potential molecular basis for neuronal 
degeneration.  Proc Natl Acad Sci USA (1993) 90 : 2628ﾝ2632.
145. Nixon RA,  Saito KI,  Grynspan F,  Griﬃ  n WR,  Katayama S, 
Honda T,  Mohan PS,  Shea TB and Beermann M : Calcium-
activated neutral proteinase (calpain) system in aging and 
Alzheimer’s disease.  Ann NY Acad Sci (1994) 747 : 77ﾝ91.
146. Liu F,  Grundke-Iqbal I,  Iqbal K,  Oda Y,  Tomizawa K and Gong 
CX : Truncation and activation of calcineurin A by calpain I in 
Alzheimer disease brain.  J Biol Chem (2005) 280 : 37755ﾝ37762.
147. Bustamante JO,  Ruknudin A and Sachs F : Stretch-activated 
channels in heart cells : relevance to cardiac hypertrophy.  J 
Cardiovasc Pharmacol (1991) 17 : S110ﾝ113.
148. Hongo K,  White E and Orchard CH : Eﬀ ect of stretch on contrac-
tion and the Ca2＋ transient in ferret ventricular muscles during 
hypoxia and acidosis.  Am J Physiol (1995) 269 : C690ﾝ697.
149. Masuda ES,  Naito Y,  Tokumitsu H,  Campbell D,  Saito F, 
Hannum C,  Arai K and Arai N : NFATx : a novel member of the 
nuclear factor of activated T cells family that is expressed pre-
dominantly in the thymus.  Mol Cell Biol (1995) 15 : 2697ﾝ2706.
150. Burkard N,  Becher J,  Heindl C,  Neyses L,  Schuh K and Ritter 
O : Targeted proteolysis sustains calcineurin activation. 
Circulation (2005) 111 : 1045ﾝ1053.
151. Iizuka K,  Kawaguchi H,  Yasuda H and Kitabatake A : The role of 
calcium activated neutral protease on myocardial cell injury in 
hypoxia.  Jpn Heart J (1992) 33 : 707ﾝ715.
152. Yoshida K,  Sorimachi Y,  Fujiwara M and Hironaka K : Calpain is 
implicated in rat myocardial injury after ischemia or reperfusion. 
Jpn Circ J (1995) 59 : 40ﾝ48.
153. Lakshmikuttyamma A,  Selvakumar P,  Kakkar R,  Kanthan R, 
Wang R and Sharma RK : Activation of calcineurin expression in 
ischemia-reperfused rat heart and in human ischemic myocardium. 
J Cell Biochem (2003) 90 : 987ﾝ997.
154. Wang HG,  Pathan N,  Ethell IM,  Krajewski S,  Yamaguchi Y, 
Shibasaki F,  McKeon F,  Bobo T,  Franke TF and Reed JC : Ca2＋
-induced apoptosis through calcineurin dephosphorylation of BAD. 
Science (1999) 284 : 339ﾝ343.
155. Mukerjee N,  McGinnis KM,  Gnegy ME and Wang KK : Caspase-
mediated calcineurin activation contributes to IL-2 release during 
T cell activation.  Biochem Biophys Res Commun (2001) 
285 : 1192ﾝ1199.
156. Springer JE,  Azbill RD,  Nottingham SA and Kennedy 
SE : Calcineurin-mediated BAD dephosphorylation activates the 
caspase-3 apoptotic cascade in traumatic spinal cord injury.  J 
Neurosci (2000) 20 : 7246ﾝ7251.
157. Rathmell JC and Thompson CB : Pathways of apoptosis in lym-
phocyte development,  homeostasis,  and disease.  Cell (2002) 
109 : S97ﾝ107.
158. Lim HW,  De Windt LJ,  Mante J,  Kimball TR,  Witt SA,  Sussman 
MA and Molkentin JD : Reversal of cardiac hypertrophy in trans-
genic disease models by calcineurin inhibition.  J Mol Cell Cardiol 
(2000) 32 : 697ﾝ709.
159. Sussman MA,  Lim HW,  Gude N,  Taigen T,  Olson EN,  Robbins J, 
Colbert MC,  Gualberto A,  Wieczorek DF and Molkentin 
JD : Prevention of cardiac hypertrophy in mice by calcineurin inhi-
bition.  Science (1998) 281 : 1690ﾝ1693.
160. Luo Z,  Shyu KG,  Gualberto A and Walsh K : Calcineurin inhibi-
tors and cardiac hypertrophy.  Nat Med (1998) 4 : 1092ﾝ1093.
161. Meguro T,  Hong C,  Asai K,  Takagi G,  McKinsey TA,  Olson EN 
and Vatner SF : Cyclosporine attenuates pressure-overload hyper-
trophy in mice while enhancing susceptibility to decompensation 
and heart failure.  Circ Res (1999) 84 : 735ﾝ740.
162. Rao A,  Luo C and Hogan PG. : Transcription factors of the NFAT 
family : regulation and function.  Annu Rev Immunol (1997)15 : 707
ﾝ747.
137Calpain-calcineurin Signaling in the Pathogenesis of Calcium-dependent DisorderJune 2007
15
Wu et al.: Calpain-calcineurin signaling in the pathogenesis of calcium-depe
Produced by The Berkeley Electronic Press, 2007
